➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Moodys
McKesson

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LUMASON

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Lumason

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02282163 ↗ Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography Recruiting Bracco Diagnostics, Inc Phase 3 2015-06-01 Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV EBD on non-contrast 2D echocardiography. Imaging conditions will represent those in routine clinical practice and will include LV EBD with harmonic imaging modality.
NCT02522481 ↗ Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141 Recruiting Bracco Diagnostics, Inc Phase 3 2015-09-01 The purpose of this study is to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who are scheduled for coronary angiography.
NCT02552238 ↗ Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142 Recruiting Bracco Diagnostics, Inc Phase 3 2015-10-01 The purpose of this study is to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who are scheduled for coronary angiography.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lumason

Condition Name

Condition Name for Lumason
Intervention Trials
Hepatocellular Carcinoma 3
Coronary Artery Disease 2
Abdominal Injury 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lumason
Intervention Trials
Abdominal Injuries 4
Carcinoma, Hepatocellular 3
Carcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lumason

Trials by Country

Trials by Country for Lumason
Location Trials
United States 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lumason
Location Trials
Pennsylvania 4
Minnesota 3
Missouri 3
California 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lumason

Clinical Trial Phase

Clinical Trial Phase for Lumason
Clinical Trial Phase Trials
Phase 4 6
Phase 3 6
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lumason
Clinical Trial Phase Trials
Recruiting 13
Not yet recruiting 12
Enrolling by invitation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lumason

Sponsor Name

Sponsor Name for Lumason
Sponsor Trials
Bracco Diagnostics, Inc 4
Children's Hospital of Philadelphia 4
Mayo Clinic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lumason
Sponsor Trials
Other 30
Industry 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Express Scripts
Colorcon
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.